糖尿病足内皮功能紊乱机制的研究进展

doi:10.3969/j.issn.1673-8640.2013.10.021

摘要/Abstract

摘要：

糖尿病足是发生于糖尿病患者的与局部神经异常和下肢远端外周血管病变相关的足部感染?溃疡和/或深层组织破坏^{[¹^],是糖尿病最严重和治疗费用最高的慢性并发症之一,严重者可截肢?糖尿病足发生的病理生理机制十分复杂,其发病机制主要涉及外周血管病变?神经病变?感染和皮肤病变几个方面^[²^]?近年来内皮细胞功能障碍与糖尿病足的关系受到越来越多的关注?大量研究表明,内皮细胞功能紊乱引起的糖尿病血管并发症在糖尿病足众多发病机制中起重要作用,是糖尿病足病理生理过程的始动环节^[³^]?充分了解内皮功能紊乱在糖尿病足血管病变中的作用,有助于进一步揭示糖尿病足的发病机制?目前认为氧化应激反应?多元醇通路激活?晚期糖基化终末产物及其受体(advanced glycation end products-receptor for AGE，AGE-RAGE)系统?蛋白激酶C(protein kinase C，PKC)信号通路的激活以及细胞因子的作用均参与内皮细胞功能紊乱的过程?我们就此方面的研究进展进行综述?}

关键词: 糖尿病足, 内皮细胞功能紊乱, 氧化应激, 一氧化氮

中图分类号:

R446.62

张莹，王伟灵. 糖尿病足内皮功能紊乱机制的研究进展[J]. 检验医学, 2013, 28(10): 948-951.

参考文献

[1] 国际糖尿病足工作组.糖尿病足国际临床指南[M]. 许樟荣,敬华,译.北京:人民军医出版社,2003:6-9.
[2] Malgrange D. Physiopathology of the diabetic foot [J].Rev Med Interne,2008,29(Suppl 2):S231-S237.
[3] 李丁,贾伟平.血糖波动与血管并发症[J].上海医学,2011,34(5):401-403.
[4] 王慧,娄晋宁.糖尿病微血管病变机制的研究进展[J].医学研究杂志,2010,39(8):101-104.
[5] Giacco F, Brownlee M. Oxidative stress and diabetic complications [J].Circ Res, 2010 ,107(9):1058-1070.
[6] Montezano AC,Touyz RM. Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases [J]. Basic ClinPharmacol Toxicol, 2012,110(1):87-94.
[7] 孟庆元,林炜栋,陈向芳. AGE-RAGE系统与糖尿病足综合征的发病机制及治疗进展[J]. 药学服务与研究,2009,9(2):118-121.
[8] Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications [J].Nat Clin Pract Endocrinol Metab,2008,4(5):285-293.
[9] 方丽,杨俊伟.糖基化终末产物介导糖尿病足细胞损伤的机制及整合素连接激酶的影响[J].中华糖尿病杂志,2010,2(5):380-383.
[10] Tuttle KR, Anderberg RJ, Cooney SK,et al. Oxidative stress mediates protein kinaes C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet [J]. Am J Nephrol,2009,29(3):171-180.
[11] Arikawa E,Ma RC, Isshiki K, et al. Effects of insulin replacements,inhibitors of angiotensin,and PKCbeta′s actions to normalize cardiac gene expression and fuel metabolism in diabetic rats [J]. Diabetes,2007,56(5):1410-1420.
[12] Folli F, Corradi D, Fanti P. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach [J].Curr Diabetes Rev, 2011,7(5):313-324.
[13] Brownlee M. The pathobiology of diabetic complications:a unifying mechanism [J].Diabetes,2005,54(6):1615-1625.
[14] Urso C, Caimi G. Oxidative stress and endothelial dysfunction [J].Minerva Med, 2011,102(1):59-77.
[15] Yilmaz MI,Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease [J].Nephrol Dial Transplant,2008,23(3):959-965.
[16] Rafikov R, Fonseca FV, Kumar S,et al. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity[J]. J Endocrinol,2011,210(3):271-284.
[17] Rogers SC, Zhang X, Azhar G, et al. Exposure to high or low glucose levels aaccelerates the appearance of markers of endothelial cell senescence and induces dysregulation of nitric oxide synthase[J].J Gerontol A Biol Sci, 2013 [Epub ahead of print].
[18] Imamura A, Takahashi R, Murakami R,et al. The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels[J].Eur J Endocrinol, 2008, 158(2):189-195.
[19] Tousoulis D, Kampoli AM, Tentolouris C,et al.The role of nitric oxide on endothelial function[J]. Curr Vasc Pharmacol,2012,10(1):4-18.
[20] Soro-Paavonen A, Zhang WZ, Venardos K, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase[J]. J Hypertens,2010,28(4):780-788.
[21] 禹远远,王瑞英,郝咏梅. 2型糖尿病与内皮细胞功能紊乱[J] .国外医学老年医学分册,2008,29(4):165-168.
[22] Uslu S, Kebapci N, Kara M,et al.Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus[J].Exp Ther Med,2012,4(1):113-120.
[23] Fasshauer M,Waldeyer T,Seeger J,et al. Serum levels of the adipokine visfatin are increased in preeclampsia[J].Clin Endocrinol(Oxf),2008,69(1):69-73.
[24] Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review[J]. Diabetes Metab Res Rev,2011, 27(6):515-527.
[25] Hector J, Schwarzloh B, Goehring J,et al. TNF-alpha alters visfatin and adiponectin levels in human fat[J].Horm Metab Res,2007,39(4):250-255.
[26] Pernow J, Shemyakin A, Bhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus[J]. Life Sci, 2012,91(13-14):507-516.
[27] Donato AJ, Gano LB, Eskurza I, et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase [J].Am J Physiol Heart Circ Physiol,2009,297(1):H425-H432.
[28] Feng J, Liu Y, Khabbaz KR, et al. Decreased contractile response to endothelin-1 of peripheral microvasculature from diabetic patients[J].Surgery,2011,149(2):247-252.
[29] Ergul A. Endothelin-1 and diabetic complications: focus on the vasculature[J].Pharmacol Res,2011 ,63(6):477-482.